The U.S. Food and Drug Administration has granted 510(k) clearance to the BD BACTEC FXI automated blood culture system, Becton, Dickinson and Company announced, clearing the device as substantially equivalent to its direct predecessor, the BD BACTEC FX.
In analytical performance studies submitted to the FDA, the BACTEC FXI demonstrated a median time-to-detection (TTD) for common bacteremic pathogens — including Staphylococcus aureus, Escherichia coli, and Candida albicans — approximately three hours shorter than the predicate BACTEC FX system under equivalent clinical loading conditions.
Blood cultures are the diagnostic backbone of sepsis workup. Sepsis mortality rises with each hour of delay before effective antibiotic administration; reducing the laboratory phase of that delay even by a few hours has downstream clinical implications. A three-hour reduction in median TTD would, if replicated in real-world hospital settings, compress the window from blood draw to positive culture and enable faster escalation from empirical broad-spectrum coverage to targeted therapy.
The BACTEC FXI is cleared for aerobic and anaerobic bacterial and fungal detection in adult and pediatric blood culture bottles. The 510(k) pathway indicates the FDA found the device substantially equivalent to a legally marketed predicate; it does not involve the full premarket approval (PMA) process used for higher-risk, novel-mechanism devices. The 510(k) clearance is distinct from PMA approval.
BD has not disclosed a commercial availability date. The BACTEC FX is currently installed across many reference laboratories and hospital microbiology departments; the FXI is expected to be offered as an upgrade pathway for existing installations.